Primary Lateral Sclerosis (PLS) is a rare adult-onset neurodegenerative disorder characterized by selective degeneration of upper motor neurons (UMNs) — the corticospinal neurons that originate in the motor cortex and project to the spinal cord[1]. Unlike amyotrophic lateral sclerosis (ALS), PLS predominantly affects UMNs with relative preservation of lower motor neurons, resulting in a clinical syndrome dominated by spasticity, hyperreflexia, and progressive motor impairment[2].
The disease typically presents in adults between 40 and 60 years of age and progresses over decades, distinguishing it from the more rapid course of ALS. Understanding the pathophysiology of UMN degeneration in PLS is critical for developing targeted therapeutic interventions and distinguishing PLS from related motor neuron disorders.
The clinical manifestations of PLS reflect the selective loss of corticospinal tract function:
Spasticity: The hallmark symptom of PLS is progressive spasticity, typically beginning in the lower extremities and spreading proximally. Spasticity results from loss of cortical inhibition on spinal motor circuits, leading to velocity-dependent increase in muscle tone[3].
Hyperreflexia: Deep tendon reflexes are markedly increased, particularly at the knee and ankle. Pathological reflexes such as the Babinski sign (extensor plantar response) and Hoffmann sign are typically present.
Muscle weakness: Progressive weakness accompanies spasticity, affecting both proximal and distal muscle groups. Weakness is typically more severe in the lower extremities initially.
Pseudobulbar affect: Some patients develop emotional lability with uncontrolled crying or laughing, reflecting corticobulbar tract involvement.
The clinical diagnosis of PLS requires:
The distinction between PLS and ALS remains challenging, as approximately 10-30% of patients initially diagnosed with PLS eventually develop lower motor neuron signs consistent with ALS[4].
The neuropathological hallmark of PLS is selective degeneration of corticospinal neurons:
Cellular changes: Betz cells — the giant pyramidal neurons in layer V of the primary motor cortex — undergo degeneration, accompanied by loss of smaller pyramidal neurons in the corticospinal tract[5]. Affected neurons show:
Axonal pathology: The descending corticospinal fibers undergo Wallerian degeneration, with loss of axonal integrity and myelin breakdown. This can be visualized with advanced neuroimaging techniques.
Gliosis: Reactive astrogliosis accompanies neuronal loss, with proliferation of astrocytes in the motor cortex and along the corticospinal pathway.
The pattern of UMN loss in PLS shows some heterogeneity:
The majority of PLS cases are sporadic, with no clear inheritance pattern. The etiology remains poorly understood, but several mechanisms have been proposed:
A small proportion of PLS cases demonstrate familial inheritance:
Magnetic resonance imaging in PLS reveals:
Cortical atrophy: Focal atrophy of the precentral gyrus and adjacent motor cortex is common. This can be quantified using voxel-based morphometry.
Corticospinal tract abnormalities: T2 hyperintensity along the corticospinal pathway, particularly in the posterior limb of the internal capsule and brainstem, is a characteristic finding.
Advanced techniques:
MRI helps distinguish PLS from:
Transcranial magnetic stimulation (TMS) reveals:
Central motor conduction time: Prolonged central motor conduction time (CMCT), reflecting corticospinal tract dysfunction.
Motor threshold: Increased resting motor threshold in PLS patients, suggesting cortical hyperexcitability.
Motor-evoked potentials: Reduced amplitude and increased latency of motor-evoked potentials.
Unlike ALS, needle EMG in PLS typically shows:
The presence of widespread denervation on EMG suggests evolution to ALS.
Neurofilament light chain (NfL) in cerebrospinal fluid and blood has emerged as a biomarker:
Current treatments for PLS focus on symptom management:
Spasticity management:
Motor symptoms:
Pseudobulbar affect: Dextromethorphan/quinidine combination
NP001: A phase 2 randomized controlled trial investigated NP001 (a macrophage migration inhibitory factor inhibitor) in PLS[8]. While the study did not meet its primary endpoint, subgroup analyses suggested potential benefit in patients with elevated inflammatory markers.
Riluzole: The only FDA-approved disease-modifying therapy for ALS has shown limited benefit in PLS. Some clinicians use it off-label, particularly in patients with rapid progression.
Future directions:
Several clinical trials are ongoing or recently completed:
The relationship between PLS and ALS remains controversial:
Common features:
Distinguishing features:
Both conditions present with spasticity, but:
SeveralPLS variants are recognized:
Singer MA, Statland JM, Wolfe GI, Barohn RJ. Primary lateral sclerosis. Journal of Neurology. 2007. ↩︎
Pradat PF, Dib M. Update on primary lateral sclerosis. Current Opinion in Neurology. 2009. ↩︎
Ferreira M, Palmieri F, Masdeu JC, Singer C. Primary lateral sclerosis: A clinical and neuropathological study. Neurology. 2019. ↩︎
Zhang L, Chen C, Song J, Li J, Liu J, Fan L, Liu M, Liu H, Tian Y, Li X, Liu X, Zhang Z, Wang Z, Liu Y, Cheng L, Liu A, Zhan S, Wang J, Sun Y, Li Y, Wang Q, Li X, Liu W, Wu L, Bai Y, Wu Y, Guo Y, Hu Y, Li H, Sun Y, Li S, Shen L, Liu X, Li J, Li M, Wang Y, Wu Y, Chen J, Wang Q, Liu Q, Sun H, Liu C, Liu Y, Wu D, Liu L, Wang C, Chen Y, Liu Y, Zhang Y, Liu C, Wang H, Liu L, Liu H, Li Z, Zhang Y. Motor neuron disease prevalence in China: A population-based survey. Lancet Regional Health. 2021. ↩︎
Turner MR, Hammers A, Al-Chalabi A, Shaw CE, Brooks DJ, Leigh PN, Piccini P. Distinct cerebral lesions in sporadic and 'D90A' SOD1 ALS: studies with [11C]-(R)-PK11195 PET. Neuroimage. 2010. ↩︎
Marsden LP, Fox PJ, Matsuoka JA, Carrow D, Estep JD, Bhattacharya V, Wong V, He GA, Ajroud-Driss S, Siddique T, Katirji B. Phenotypic heterogeneity in hereditary and sporadic primary lateral sclerosis. Neurology. 2012. ↩︎
Gethalany C, Snyder R, Goudreau J, McCluskey L, Malani A, Singer C, Sharma J, Chan S, Garvin-Cade J, Pioro E, Moore D, Swenson A, Kaur S, McGovern R, Andrews J, Karg B, Miller R, Clawson L, Bruijn L, Cudkowicz M. Neurofilament light chain as a biomarker in primary lateral sclerosis. Annals of Clinical and Translational Neurology. 2018. ↩︎
Smith E, glass JD, Zou J, Miller RG, Hiipakka P, Luthra K, Kaji R, Bostrom K, Foust L, Beers D, Goyal N, Pattee G, Cudkowicz M, Sava M, Heitzman D. A phase 2 randomized trial of NP001 in primary lateral sclerosis. Neurology. 2020. ↩︎